Jennifer Ficenec: What Happens to Blood Products After Hospitals Say No?
Jennifer Ficenec, Executive Vice President at Blood Centers of America, shared on LinkedIn:
”The Upcycling Mindset: What Happens to Blood Products After Hospitals Say No?
Blood and – any of its components – has a limited shelf life during which it is safe for transfusion.
What happens when it is no longer safe for transfusion?
We can repurpose blood and its components to be used in:
– research
– manufacturing
– lab training.
What does it mean? Researchers need live cells and blood-based components as controls or for their experiments.
Sometime we need to test the response of real human cells to new innovations such as chemical compounds, medical devise, or the plastic that is used to handle blood.
Another use is for the training of students and lab personnel on how to handle blood, and its components is essential.
At BCA, we are committed to finding “𝘭𝘪𝘧𝘦” 𝘢𝘯𝘥 “𝘱𝘶𝘳𝘱𝘰𝘴𝘦” to those blood and blood-based components we collected from donors to give more use to research and scientific manufacturing community, not just those who need blood or its components directly.
Yes collected blood is used in transfusions by patients who suffered accidents but there are also those who suffer from immune diseases, cancer and other conditions where the blood or blood-based components can be used to treat or research treatments.
Learn more about upcycled products, including LRS chambers that are available for purchase.
Follow us for more on cell therapy innovation and our commitment to patients.”
Stay updated on the emerging with Hemostasis Today.
-
Jan 16, 2026, 13:15Paul Bolaji Invites You to Join World Stroke Organization Membership
-
Jan 16, 2026, 12:59Prithu Sundd on The Role of CD39 Polymorphism in Enabling Pulmonary Thrombosis in SCD
-
Jan 16, 2026, 12:46Gregory Piazza on The Effect of Enduring Risk Factors in Provoked VTE
-
Jan 16, 2026, 12:33Fernando Corrales-Medina on Heavy Periods in Teens: Don’t Miss a Bleeding Disorder
-
Jan 16, 2026, 06:05Wolfgang Miesbach on Jacob Lund’s Study: How to Define FVIII Bioequivalence
-
Jan 16, 2026, 05:52Piotr Czempik Shares His Latest Contribution to Acta Haematologica Polonic
-
Jan 16, 2026, 05:44Florian Piekarski on Perioperative Blood Management When Allogeneic Transfusion is Not Aaccepted
-
Jan 16, 2026, 05:00Plaque Rupture and Thrombosis
-
Jan 16, 2026, 04:52Arterial Disease Across Vascular Beds․ Lipoprotein(a) as a Causal Risk Factor